AstraZeneca Pharma India declined 1.57% to Rs 9,878 after the company said its managing director (MD), Sanjeev Kumar Panchal has resigned from his position with effect from the close of business on 30 ...

Comparative assessments and other editorial opinions are those of U.S. News and have not been previously reviewed, approved ...

Sanjay Kumar Bohra has stepped down from his role as Chief Financial Officer (CFO) of Force Motors, effective June 9. The ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

IonQ shares traded higher Monday after the company announced results of a collaborative research program with AstraZeneca, ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

In an effort to greater prepare HCPs and to avoid potential shortages, the company targets Q3 as the shipment date.

IonQ announced the acquisition of a UK rival Monday and unveiled results of a collaboration involving semiconductor titan Nvidia.

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...